Handbook of benign hematology / editors: Martha Pritchett Mims [and two others].

https://portal.igpublish.com/iglibrary/obj/SPCB0002173?searchid=1628751487073oXizJjVUNGHkOnSfjGttS

Include bibliographical references and index

1. Overview of normal hematopoiesis -- 2. Neutrophil disorders -- 3. Myeloid disorders -- 4. Acquired aplastic anemia and inherited bone marrow failure syndromes -- 5. Myeloproliferative neoplasms -- 6. Hypoproliferative anemia -- 7. Approach to hemolytic anemias -- 8. Thalassemia and hemoglobinopathies -- 9. Iron metabolism disorders and porphyria -- 10. Platelet disorders -- 11. Disorders of coagulation -- 12. Venous thromboembolism -- 13. Lymphoid disorders -- 14. Transfusion medicine -- 15. Pharmacology

"Handbook of Benign Hematology is a practical guide to the diagnosis and management of benign hematologic conditions. The book begins with a chapter on normal hematopoiesis and follows with chapters devoted to different groups of blood disorders and syndromes including neutrophil disorders, non-malignant myeloid disorders, bone marrow failure syndromes, myeloproliferative disorders, hypoproliferative anemia, hemolytic anemia, iron metabolism disorders and porphyria, platelet disorders, hemostasis and coagulation defects, and thrombosis. Each subtype of the disorder covered within the chapters features a clinical case, an introduction to the condition, details on diagnosis including applicable criteria and lab work needed, key diagnostic dilemmas when conducting a differential diagnosis, prognosis, treatment options, details on clinical trials and emerging clinical strategies, and bulleted key points which highlight clinical pearls and common pitfalls. Important seminal and practice-changing references conclude each chapter. The final chapters provide best practices for transfusion medicine and a guide to pharmacologic agents and their uses in clinical practice for adult and pediatric patients. The handbook is filled with tables and illustrations which highlight FDA-approved drug information, clinical trials data, hematopathologic characteristics of different disorders, important management criteria and more. The result is a uniform and engaging approach that clinicians and practitioners can easily follow and use in practice or for review"--Provided by publisher.

Fund 164 CE-Logic, Inc. Purchased March 2, 2021 OEBP000185 P. Roderno PHP 10,978.00
2021-03-110 7813 to 7820